AVE 8488
Alternative Names: AVE8488Latest Information Update: 18 Mar 2009
At a glance
- Originator sanofi-aventis
- Class Sleep disorder therapies
- Mechanism of Action Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Insomnia
Most Recent Events
- 31 Aug 2005 Preclinical trials in Sleep disorders in France (unspecified route)